Phase 3 #HERTHENA-Lung02 study: ▫️HER3-DXd v chemo in EGFRm NSCLC post 3G TKI ▫️mPFS: 5.8 v 5.4 mo (HR 0.77) ▫️ORR: 35% v 25% ▫️🧠PFS: 5.4 v 4.2 mo (HR 0.75) ▫️TEAEs G≥3: 73% v 57%, mostly thrombocytopenia ▫️5% ILD (w/ 2 G5 events) #ASCO25 @EGFRResisters @OncoAlert

In this #LungCancerConsidered, we discussed in Korean emerging treatments for EGFR+ and HER2+ mutant NSCLC as well as SCLC. Grateful to Dr. @Sokim_33 and Dr. Se-Hoon Lee for sharing their expert insights! 많은 청취 부탁드립니다. Listen here: https://t.co/gNCuL1eTqv

Interested in an updated overview of small cell lung cancer geared towards a general audience? Check out our review article published in JAMA! @Sokim_33 @Annechiangmd @YaleMed @YaleCancer @YaleRadOnc

Group photo before recording the 4th Korean episode of @IASLC Lung Cancer Considered with Drs. Se-Hoon Lee and @Sokim_33! We discussed the evolving landscape of EGFR and HER2 mutant NSCLC, the role of targeted therapy & IO in early-stage NSCLC, and emerging treatments for SCLC.

Our attempt at the Ellen ‘Oscar selfie’ at the @JTOonline reviewer workshop before leaving San Diego! Thank you to the faculty @DrAlexAdjei @KarenReckampMD @oncoOuLungCA @vs_lim for such an amazing last day at #WCLC24 @IASLC #lcsm

Data on Dato- encouraging!

The efficacy of #immunotherapy is mainly attributed to reactivation of CD8+ T cells that specifically recognize tumour antigens in a MHC-I-context. There is new evidence that CD4+ T cells can contribute to antitumour immunity, independent of their role as helpers and regulators

About last night. A feast! They had to place a small table behind us for additional food plates which didn’t fit on the table. Amr knows how to welcome the guests to Cleveland! It’s been fun! @NANETS1

An analysis by @Sokim_33 @AminNassarMD & colleagues of treatment options for patients with stage III unresectable EGFR mutant #NSCLC showed consolidation EGFR TKI therapy yielded significantly longer disease free survival than durvalumab #ASCO23 #lcsm @SmilowCancer @YaleMed @YNHH

#AACR23 Is #AEGEAN a sea change? - Ph III neodj durva+chemo + 1yr durva post surgery v chemo alone in early stage NSCLC - 70% stage III - EFS HR 0.68, pCR 17% v 4% - cis or carbo had equiv EFS - ?females did not do as well for EFS or pCR - more data needed @OncoAlert #LCSM

2 for the price of..0! Cambridge Press Elements in Molecular Oncology chapters on precision oncology in NSCLC- EGFR + beyond -available for download for free for 1 wk before paywall comes up https://t.co/qi8bqNCtFh

BFAST but be smart! @DrRoyHerbstYale & @Sokim_33 discuss results of a phase III trial evaluating blood-based tumor mutational burden in patients with treatment-naive advanced-stage #NSCLC in @NatureRevCancer. #lcsm @OncoAlert @SmilowCancer @YaleMed @YNHH https://t.co/sl5j6g0M9N

Credits to the whole team! @DrSteveMartin @slowwalker919 @StephenVLiu @HaiyingCheng @PatrickCMa1 @chulkimMD @ReckampK @dipeshuprety4 @MNagasaka

Extensive characterization of #METex14 NSCLC in #JTOCRR by Drs. @Sokim_33 @DrSteveMartin. Included 21582 samples tested with NGS: METex14 seen in 533 (2.5%). Analysis noted common co-alterations in MDM2, HMGA2, CDK4 more common in MET altered vs wild type. https://t.co/y3RJei5X6E